219
Participants
Start Date
November 15, 2013
Primary Completion Date
May 20, 2015
Study Completion Date
December 5, 2015
Placebo
Participants will receive placebo once daily
JNJ-54781532 25 mg once daily
Participants will receive 25 mg of JNJ-54781532 once daily
JNJ-54781532 75 mg once daily
Participants will receive 75 mg of JNJ-54781532 once daily
JNJ-54781532 150 mg once daily
Participants will receive 150 mg of JNJ-54781532 once daily
JNJ-54781532 75 mg twice daily
Participants will receive 75 mg of JNJ-54781532 twice daily
La Jolla
Thornton
Ann Arbor
Tupelo
Egg Harbor
Salisbury
Cleveland
Lima
Norman
Germantown
Nashville
San Antonio
Chesapeake
Fairfax
Seattle
Bankstown
Bedford
Concord
Herston
Launceston
Melbourne
Penrith
South Brisbane
Brussels
Ghent
Kortrijk
Leuven
Pleven
Sofia
Varna
Calgary
Vancouver
Winnipeg
Greater Sudbury
London
Ottawa
Toronto
Montreal
Lille
Paris
Pessac
Berlin
Essen
Frankfurt A. M.
Hanover
Heidelberg
Herne
Jena
Kiel
Magdeburg
Münster
Neustadt
Stade
Békéscsaba
Budapest
Mosonmagyaróvár
Szekszárd
Hadera
Haifa
Jerusalem
Nazareth
Ramat Gan
Rehovot
Amsterdam
Amsterdam-Zuidoost
Maastricht
Rotterdam
Elblag
Lodz
Sopot
Warsaw
Bucharest
Constanța
Iași
Timișoara
Kazan’
Nizny Novgorod
Novosibirsk
Omsk
Rostov-on-Don
Ryazan
Saint Petersburg
Stavropol
Ufa
Yaroslavl
Donetsk
Ivano-Frankivsk
Kharkiv
Kiev
Kyiv
Lviv
Odesa
Ternopil
Uzhhorod
Vinnitsa
Zaporizhzhia
Zhaporozhia 69104
Janssen Research & Development, LLC
INDUSTRY